Characteristic analysis of adverse reactions of five anti-TNFɑ agents: a descriptive analysis from WHO-VigiAccess [PDF]
Frontiers in Pharmacology, 2023 Introduction: Tumor necrosis factor (TNF) inhibitors (adalimumab, infliximab, etanercept, golimumab, and certolizumab pegol) have revolutionized the treatment of severe immune-mediated inflammatory diseases, including rheumatoid arthritis, Crohn’s ...
Ruxu You
exaly +6 more sources
Characteristic analysis of adverse reactions of histone deacetylase inhibitors based on WHO-VigiAccess [PDF]
Frontiers in PharmacologyBackgroundThis study assessed the adverse drug reactions (ADRs) associated with HDAC inhibitors using the VigiAccess database maintained by the World Health Organization (WHO).
Xinran Feng, Yumeng Lin
exaly +6 more sources
The real-world analysis of adverse events with azacitidine: a pharmacovigilance study based on the FAERS and WHO-VigiAccess databases [PDF]
Frontiers in PharmacologyBackgroundAzacitidine is used to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It acts as a cytosine analog and DNA methyltransferase inhibitor, inducing DNA hypomethylation to reverse epigenetic modifications and restore normal ...
Youfu He, Zhaorui Wang, Linlin Guo
exaly +6 more sources
The characteristics of adverse reactions of three anti-prostate cancer drugs based on Vigiaccess database and bibliometric analysis [PDF]
Frontiers in PharmacologyBackgroundAndrogen antagonists, including apalutamide, darolutamide, and enzalutamide, play a crucial role in the treatment of prostate cancer.
Liwei Zhang, Jiangjie Chen
exaly +6 more sources
Adverse event profile of fondaparinux sodium: a disproportionality analysis based on FAERS, JADER, and VigiAccess databases [PDF]
Frontiers in MedicineBackgroundFondaparinux sodium, a synthetic pentose sugar, selectively inhibits factor Xa and is mainly used to prevent venous thromboembolism during major lower extremity orthopedic surgeries. It is also utilized for treating unstable angina pectoris and
Wei Jin, Jianwei Pan, Lin Yu, Menglu Zhu
doaj +6 more sources
Adverse reactions of four multi-targeted tyrosine kinase inhibitors: a descriptive analysis of the WHO-VigiAccess database [PDF]
Frontiers in PharmacologyBackgroundThe introduction of multi-targeted tyrosine kinase inhibitors (MTKIs) such as axitinib, lenvatinib, sorafenib, and sunitinib has greatly broadened the available treatment options for Renal Cell Carcinoma (RCC).
Xuefan Zeng
exaly +6 more sources
Characterization of skin adverse events associated with cetuximab: real-world insights from the two global pharmacovigilance databases of FAERS and VigiAccess [PDF]
Frontiers in OncologyBackgroundCetuximab, an IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is widely used in metastatic colorectal cancer and other solid tumors. Cutaneous adverse events (AEs) are among its most frequent toxicities, but real-
Chenwen Li +8 more
doaj +3 more sources
Adverse events of givosiran in the treatment of acute hepatic porphyria: a pharmacovigilance study using the FAERS and VigiAccess databases [PDF]
Orphanet Journal of Rare DiseasesBackground Acute hepatic porphyria is a rare metabolic disorder characterized by life-threatening acute attacks and chronic neurological symptoms. Givosiran is an RNA interference therapeutic approved by the FDA in 2019 to treat AHP by inhibiting hepatic
Yinpeng Xu +4 more
doaj +3 more sources
Characteristics of adverse reactions of three anti-glioma drugs in WHO-VigiAccess [PDF]
Frontiers in PharmacologyIntroductionAntitumor medications such as Avastin, Berubicin, and Temozolomide have fundamentally transformed the treatment landscape for gliomas by exhibiting potent pharmacological effects on both high-grade and low-grade gliomas.
Huadong Ke +7 more
doaj +4 more sources
Real-world study of adverse events associated with sodium zirconium cyclosilicate based on FDA adverse event reporting system and VigiAccess database. [PDF]
PLoS ONEThe aim of this study was to investigate frequencies, types, and signals of adverse drug events (ADEs) associated with sodium zirconium cyclosilicate (SZC) used for the treatment of hyperkalemia, in order to inform clinicians of possible safety concerns ...
Xiaona Jia, Lei Liu, Pan Wang
doaj +3 more sources